Skip to main content

Table 3 Pooled adverse events of endostatin combined with radiotherapy or chemoradiotherapy

From: Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis

Events Grade Incidence, % (95% CI)
Overall ECRT group ERT group
Radiation pneumonitis All 55.9 (31.4–77.9) 50.7 (20.9–80.0) 64.1 (27.3–89.4)
≥3 10.9 (5.4–20.8) 11.9 (4.5–27.9) 9.4 (3.3–24.0)
Radiation esophagitis All 77.4 (69.4–83.7) 89.7 (83.1–93.9) 55.5 (40.9–69.3)
≥3 11.6 (7.6–17.5) 12.2 (7.6–19.0) 9.4 (3.3–24.0)
Neutropenia All 76.5 (55.6–89.4) 85.7 (78.5–90.7) 25.1 (71.6–89.9)
≥3 27.8 (14.3–47.0) 40.1 (30.3–50.8) 2.1 (0.3–13.7)
Leukopenia All 84.5 (49.7–96.8) 91.8 (78.2–97.2) 40
≥3 35.5 (18.5–57.7) 43.4 (27.2–61.2) 0
Anemia All 54.7 (34.7–73.3) 70.5 (62.1–77.6) 28.9 (17.6–43.6)
≥3 10.5 (6.2–17.2) 12.3 (7.6–19.1) 2.1 (0.3–13.7)
Thrombocytopenia All 46.0 (23.2–59.3) 52.5 (34.2–70.2) 35.7 (23.1–50.7)
≥3 6.9 (2.4–18.3) 10.1 (3.3–26.7) 2.1 (0.3–13.7)
Nausea/vomiting All 48.2 (32.5–64.2) 54.1 (38.7–68.7) 40
≥3 5.8 (2.8–11.6) 6.3 (3.0–12.9) 0
Arrhythmia All 25.7 (9.5–52.7) 37 15
≥3 0 0 0
Fatigue All 58.0 (39.3–74.7) 67.4 (56.7–76.5) 40
≥3 2.6 (0.7–8.7) 2.7 (0.7–1.3) 0
Hemorrhage All NR 15.2 (9.0–24.5) NR
≥3 NR 1.8 (0.4–8.3) NR
Hypertension All NR 2 NR
≥3 NR 0 NR
  1. ERT Endostatin combined with radiotherapy, ECRT Endostatin combined with concurrent chemoradiotherapy, NR Not reported